References
- Fernandez-Checa JC, Takikawa H, Horie T, Ookhtens M, Kaplowitz N. Canalicular transport of reduced glutathione in normal and mutant Eisai hyperbilirubinemic rats. Journal of Biological Chemistry 1992; 267: 1667–1673
- Hagmann WK. The discovery and potential of N-sulfonylated dipeptide VLA-4 antagonists. Current Topics in Medicinal Chemistry 2004; 4: 1461–1471
- Hagmann WK, Durette PL, Lanza T, Kevin NJ, De Laszlo SE, et al. The discovery of sulfonylated dipeptides as potent VLA-4 antagonists. Bioorganic and Medicinal Chemistry Letters 2001; 11: 2709–2713
- Hemler ME, Elices MJ, Parker C, Takada Y. Structure of the integrin VLA-4 and its cell–cell and cell–matrix adhesion functions. Immunological Reviews 1990; 114: 45–65
- Huryn DM, Konradi AW, Ashwell S, Freedman SB, Lombardo LJ, Pleiss MA, Thorsett E, Yednock T, Kennedy JD. The identification and optimization of orally efficacious small molecule VLA-4 antagonists. Current Topics in Medicinal Chemistry 2004; 4: 1473–1484
- Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, Horner HC. A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. Journal of Neuroimmunology 1995; 58: 1–10
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nature Reviews 2004; 3: 711–715
- Lee Y-C, Zocharski PD, Samas B. An intravenous formulation decision tree for discovery compound formulation development. International Journal of Pharmaceutics 2003; 253: 111–119
- MacCoss M, Baillie TA. Organic chemistry in drug discovery. Science 2004; 303: 1810–1813
- Neervannan S. Preclinical formulations for discovery and toxicology: physiochemical challenges. Expert Opinion on Drug Metabolism and Toxicology 2006; 2: 715–731
- Porter JR. Novel VLA-4 antagonists. Drugs 2000; 3: 788–798
- Raucy JL, Lasker JM. Isolation of P450 enzymes from human liver. Methods in Enzymology 1991; 206: 577–587
- Roman ID, Monte MJ, Gonzalez-Buitrago JM, Esteller A, Jimenez R. Inhibition of hepatocytary vesicular transport by cyclosporin A in the rat: relationship with cholestasis and hyperbilirubinemia. Hepatology 1990; 12: 83–91
- Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, Sugiyama Y. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin–Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Molecular Pharmacology 2004; 66: 450–459
- Shitara Y, Iyoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug–drug interaction between cerivastatin and cyclosporin A. Journal of Pharmacology and Experimental Therapeutics 2003; 304: 610–616
- Takenaka O, Horie T, Kobayashi K, Suzuki H, Sugiyama Y. Kinetic analysis of hepatobiliary transport for conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia. Pharmaceutical Research 1995; 12: 1746–1755
- Tilley JW, Sidduri A. VLA-4 antagonists. Drugs of the Future 2002; 26: 985–998
- Tong XS, Wang J, Zheng S, Pivnichny JV. High-throughput pharmacokinetics screen of VLA-4 antagonists by LC/MS/MS coupled with automated solid-phase extraction sample preparation. Journal of Pharmaceutical and Biomedical Analysis 2004; 35: 867–877
- Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Medicinal Research Reviews 2002; 22: 146–167